About Modulus Therapeutics
Modulus Therapeutics is a company based in Seattle (United States) founded in 2020 by Bryce Daines.. Modulus Therapeutics has raised $3.5 million across 1 funding round from investors including Allen Institute for Artificial Intelligence, Madrona and KdT Ventures. Modulus Therapeutics offers products and services including CAR-NK Therapy, Switch Receptor Arrays, and NK-specific CARs. Modulus Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Seattle, United States
- Founders Bryce Daines
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Modulus Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$3.5 M (USD)
in 1 rounds
-
Latest Funding Round
$3.5 M (USD), Seed
Jul 15, 2021
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Modulus Therapeutics
Modulus Therapeutics offers a comprehensive portfolio of products and services, including CAR-NK Therapy, Switch Receptor Arrays, and NK-specific CARs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Engineered NK cells for safe treatment of autoimmune diseases.
Platform for controlling cell therapy activity in response to signals.
Custom receptors enhancing persistence and cytotoxicity in immune cells.
Unlock access to complete
Unlock access to complete
Funding Insights of Modulus Therapeutics
Modulus Therapeutics has successfully raised a total of $3.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $3.5 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $3.5M
-
First Round
First Round
(15 Jul 2021)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Seed - Modulus Therapeutics | Valuation | Madrona Venture Group |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Modulus Therapeutics
Modulus Therapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Allen Institute for Artificial Intelligence, Madrona and KdT Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investing in AI, biotech, and technology sectors, focusing on seed and early stages in Seattle and beyond.
|
Founded Year | Domain | Location | |
|
Early-stage investments are made in frontier science ventures.
|
Founded Year | Domain | Location | |
|
Provider of AI research, natural language processing, and computer vision services
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Modulus Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Modulus Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Modulus Therapeutics Comparisons
Competitors of Modulus Therapeutics
Modulus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Modulus Therapeutics
Frequently Asked Questions about Modulus Therapeutics
When was Modulus Therapeutics founded?
Modulus Therapeutics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Where is Modulus Therapeutics located?
Modulus Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is Modulus Therapeutics a funded company?
Modulus Therapeutics is a funded company, having raised a total of $3.5M across 1 funding round to date. The company's 1st funding round was a Seed of $3.5M, raised on Jul 15, 2021.
What does Modulus Therapeutics do?
Founded in 2020, Modulus Therapeutics is based in Seattle, United States, and operates in the biotechnology sector. Immune cell therapies targeting solid tumors are developed using the Convergent Design platform. This approach integrates genetic engineering, machine learning, multi-omics analysis, and in-vivo screening of candidates in animal models to advance therapeutic options.
Who are the top competitors of Modulus Therapeutics?
Modulus Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
What products or services does Modulus Therapeutics offer?
Modulus Therapeutics offers CAR-NK Therapy, Switch Receptor Arrays, and NK-specific CARs.
Who are Modulus Therapeutics's investors?
Modulus Therapeutics has 3 investors. Key investors include Allen Institute for Artificial Intelligence, Madrona, and KdT Ventures.